Mental Health or Cardiac Health. Is there a reason to choose? Cardiac arrhythmias induced by Atomoxetine and Methylphenidate

Abstract

The current treatment of Attention Deficit Disorder and Attention Deficit with Hyperactivity consists mainly in the administration of Straterra (Atomoxetine) Concerta and Ritalin (Methylphenidate). The FDA warned that the products might increase systolic, diastolic blood pressure, and lead to ventricular arrhythmias. Arrhythmic events and sudden cardiac death were described in adults with preexistent heart disease. However, studies on children have failed to demonstrate a clear association between the arrhythmic events and these drugs, as demonstrated in adults. What should the attitude of the pediatric psychiatrist be towards the administration of these products? What examination should be made by the psychiatrist before referring the child to a pediatric cardiologist? Which patients need a cardiology consultation before the administration of these products? What is the follow-up after drug initiation? These are some questions that this paper aims to answer.

Keywords

• atomoxetine
• metilphenidate
• arrhythmia
• stimulants
• cardiac